Replies to post #2529 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA updated corporate slide set (5/8/23):

https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4

The main difference between the 5/8/23 corporate slide set and the previous version (dated 4/18/23) is three new slides containing data from the EDP-235 phase-2 SPRINT trial. Specific changes in the slide set:

• New Slide 22 has essentially the same info as old Slide 22, but the wording has been shuffled a bit. (The bullet point re 95% bioavailability in rats is gone.)

• Slide 25 is the same as old Slide 26; Slide 26 is the same as old Slide 27; and Slide 30 is the same as old Slide 25.

• Slides 27-29, which contain results from the EDP-235 phase-2 SPRINT trial, replace old Slide 28. (See https://ir.enanta.com/static-files/c9eca2f1-296c-4a0c-9ce4-d668229f1ec5 for the complete slide set for the SPRINT trial.)

• Slides 31-40 are the same as old Slides 29-38 — i.e. subtract “2” from the new slide number to get the corresponding old slide number.

• Slides 37-38, which contain updated financial data, supersede old slides 35-36. Slide 37 has an error of omission insofar as it doesn’t mention the partial monetization of Mavyret royalties starting in 3Q23.